EditForce, Inc., based in Fukuoka, Japan, has signed a License Agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop, and commercialize gene therapy products targeting a specific central nervous system (CNS) disease. This collaboration will utilize EditForce’s proprietary PPR protein platform technology, combining EditForce’s biotechnology innovations with MTPC’s expertise in drug development and global commercialization.

As part of the deal, MTPC gains exclusive global rights for drug candidate selection, preclinical and clinical development, manufacturing, and commercialization. EditForce will receive upfront and milestone payments exceeding 20 billion yen, as well as royalties from worldwide sales following product launch.

EditForce’s CEO, Takashi Ono, expressed enthusiasm for the partnership, noting that the collaboration aims to deliver breakthrough pharmaceutical products to patients. The company’s PPR technology enables precise DNA and RNA editing, which could lead to novel therapies for CNS diseases.

Mitsubishi Tanabe Pharma, a subsidiary of the Mitsubishi Chemical Group, is one of Japan’s oldest pharmaceutical firms and focuses on precision medicine in CNS and immuno-inflammation fields. The partnership aligns with both companies’ missions to advance therapeutic innovation.